{"name":"SAGE Category","title":"","children":[{"id":"discovery","name":"discovery","presenterLast":"discovery","children":[{"id":2186,"name":2186,"title":"High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing","presenterFirst":"Patrick","presenterLast":"Lizotte","keywords":"Epidermal growth factor receptor;Antigen presentation;Immunotherapy;CRISPR/Cas9","target":"EGFR","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":2320,"name":2320,"title":"Depletion of blood arginine with pegzilarginase (AEB1102) in combination with anti-PD-L1 increases tumor infiltration by immune cells and enhances antitumor activity","presenterFirst":"Giulia","presenterLast":"Agnello","keywords":"Arginine deprivation;Tumor microenvironment;Metabolism;Checkpoint inhibitors","target":"arginase1","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2325,"name":2325,"title":"Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models","presenterFirst":"Sarah","presenterLast":"Wang","keywords":"Combination studies;Checkpoint;PARP;Combination therapy","target":"PARP1/2","tumor":"ovarian","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3402,"name":3402,"title":"An epigenetic and immunologic approach to optimize therapy for HNSCC","presenterFirst":"Rachel","presenterLast":"Goldberg","keywords":"Epigenetics;Immunotherapy;Head and neck cancer","target":"DNAMT","tumor":"headneck","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5135,"name":5135,"title":"Targeting CX3CR1 Impairs the reseeding and colonization of circulating tumor cells and decelerates metastatic progression","presenterFirst":"Chen","presenterLast":"Qian","keywords":"Circulating tumor cells;Metastasis;Combination therapy","target":"CX3CR1","tumor":"breast","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5151,"name":5151,"title":"Targeting glutamine metabolism as a means of enhancing antitumor T-cell responses","presenterFirst":"Robert","presenterLast":"Leone","keywords":"Immunotherapy;Metabolism;Checkpoint;Glutamine","target":"glutamine","tumor":"NA","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":7441,"name":7441,"title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"gastric_headneck_lymphoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7521,"name":7521,"title":"Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing","presenterFirst":"Kathryn","presenterLast":"Fraser","keywords":"Natural killer cells;Immunotherapy;Antibody","target":"PAMP","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7608,"name":7608,"title":"Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor","presenterFirst":"Jeremy","presenterLast":"Tchaicha","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Tumor microenvironment","target":"AHR","tumor":"melanoma_colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8314,"name":8314,"title":"T-cell activation through the inhibition of tumor-expressed IDO1 activity in tryptophan metabolism pathway","presenterFirst":"Frank","presenterLast":"Xing","keywords":"T cell;IDO1","target":"IDO1","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"drug","name":"drug","presenterLast":"drug","children":[{"id":2082,"name":2082,"title":"Novel small-molecule inhibitor of PD1/PDL1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy","presenterFirst":"Yuguang","presenterLast":"Wang","keywords":"Immunotherapy;Small molecule PD1/PDL1 inhibitor;anti-CTLA4;Epacadostat","target":"PD1/L1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2290,"name":2290,"title":"Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody","presenterFirst":"Yosuke","presenterLast":"Ota","keywords":"Combination therapy;TLR7;PD-1;memory T cell","target":"TLR7","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2544,"name":2544,"title":"TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoint inhibitor antitumor activity in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","keywords":"Immunostimulation;Innate immunity;Checkpoint;Antitumor activity","target":"TLR9","tumor":"colorectal_lymphoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2562,"name":2562,"title":"EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic","presenterFirst":"Srinivas","presenterLast":"Gullapalli","keywords":"Cancer immunotherapy;Checkpoint;Tumor microenvironment;Drug discovery","target":"IDO1_TD2","tumor":"colorectal_melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3556,"name":3556,"title":"Discovery and optimization of potent and selective inhibitors of USP7 to enhance anti-tumor immunity and target tumor growth","presenterFirst":"Paul","presenterLast":"Kassner","keywords":"Tumor immunity;Regulatory T cell;Deubiquitinase inhibitor;p53","target":"USP7","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical in vitro"},{"id":3846,"name":3846,"title":"Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models","presenterFirst":"Yifan","presenterLast":"Zhai","keywords":"IAP;Checkpoint;Immunotherapy","target":"IAP","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":4634,"name":4634,"title":"Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer","presenterFirst":"Dhanalakshmi","presenterLast":"Sivanandhan","keywords":"Small molecule inhibitor;Epigenetics","target":"LSD1_HDAC","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5170,"name":5170,"title":"Metabolic modulation of the tumor microenvironment using Synthetic Biotic\u2122 Medicines","presenterFirst":"Kip","presenterLast":"West","keywords":"Immunotherapy;Immunomodulation;Tumor microenvironment;Bacterial treatment","target":"KYN","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6119,"name":6119,"title":"NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders","presenterFirst":"Izhak","presenterLast":"Haviv","keywords":"Drug resistance;Immunomodulation;Combination therapy;Efficacy","target":"STAT3_IRS1/2","tumor":"multiple","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6137,"name":6137,"title":"Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies","presenterFirst":"Katharina","presenterLast":"Deschler","keywords":"Innate immunity;Checkpoint;T lymphocytes","target":"TLR7/8","tumor":"melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6433,"name":6433,"title":"Identification and characterization of the IDO1 inhibitor LY3381916","presenterFirst":"Frank","presenterLast":"Dorsey","keywords":"Immunomodulation;Small molecule inhibitor;Immunotherapy;Lung cancer","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6912,"name":6912,"title":"Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214","presenterFirst":"Saul","presenterLast":"Kivimae","keywords":"Dendritic cells;Tumor immunity;Cancer immunotherapy;T cell","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7442,"name":7442,"title":"Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine","presenterFirst":"Xiaoyan","presenterLast":"Zhang","keywords":"Immunotherapy;Tumor microenvironment","target":"KYN","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"target-tumor","name":"target-tumor","presenterLast":"target-tumor","children":[{"id":2090,"name":2090,"title":"Glycogen synthase kinase (GSK-3) inactivation downregulates PD-1 and synergizes with PD-1/PL1 and CTLA-4 blockade in cancer immunotherapy","presenterFirst":"Christopher","presenterLast":"Rudd","keywords":"T cell;Cancer immunotherapy;Combination therapy;melanoma","target":"GSK-3","tumor":"melanoma_lymphoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":2952,"name":2952,"title":"Identifying characteristics of orthotopic HCC mouse models to predict response to immunotherapy","presenterFirst":"Carina","presenterLast":"Hage","keywords":"Hepatocellular carcinoma;Immunotherapy;Mouse models;Combination therapy","target":"TLR7/8","tumor":"hcc","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3070,"name":3070,"title":"Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models","presenterFirst":"Daqing","presenterLast":"Wang","keywords":"Immunotherapy;Tumor microenvironment;Immunomodulation;Combination therapy","target":"TLR9","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3158,"name":3158,"title":"The combination of CXCR4 and checkpoint receptor inhibition improves survival in an orthotopic murine glioma model","presenterFirst":"Adela","presenterLast":"Wu","keywords":"CXCR4;Checkpoint;Angiogenesis;Glioma","target":"CXCR7","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":3285,"name":3285,"title":"Preclinical study of a novel TLR8 selective agonist for cancer immunotherapy","presenterFirst":"Yuxun","presenterLast":"Wang","keywords":"Cancer immunotherapy;Targeted therapy;Innate immunity;Drug discovery","target":"TLR8","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3522,"name":3522,"title":"Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade","presenterFirst":"Qihong","presenterLast":"Zhao","keywords":"Chemokine receptor;Immunosuppression;CCR2/5;Tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"colorectal_breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3759,"name":3759,"title":"Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRP\u03b1 axis","presenterFirst":"Murali","presenterLast":"Ramachandra","keywords":"Immunotherapy;Small molecule drugs;Macrophages;Innate immunity","target":"CD47_SIRP","tumor":"colorectal_lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3790,"name":3790,"title":"Dual inhibitor of immunokinase and pan-RAF for the treatment of KRAS-mutated cancers","presenterFirst":"Sungpyo","presenterLast":"Hong","keywords":"Immunotherapy;M-CSF;Macrophages;RAF kinase","target":"CSF1-R","tumor":"colorectal_breast","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5025,"name":5025,"title":"Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors","presenterFirst":"Samanthi","presenterLast":"Perera","keywords":"Immunotherapy;Innate immunity;Adoptive immunotherapy;Mouse models","target":"STING","tumor":"melanoma_colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5311,"name":5311,"title":"CXCR4 inhibition modulates tumor microenvironment and robustly inhibits growth of B16-OVA melanoma","presenterFirst":"James","presenterLast":"Mier","keywords":"CXCR4;T cell;melanoma","target":"CXCR4","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5613,"name":5613,"title":"Epigenetic modulation of the tumor microenvironment enhances immune checkpoint efficacy in a murine model of pancreatic cancer","presenterFirst":"Brian","presenterLast":"Christmas","keywords":"Pancreatic cancer;Epigenetics;Checkpoint;Tumor microenvironment","target":"HDAC","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5631,"name":5631,"title":"X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma","presenterFirst":"Robert","presenterLast":"Andtbacka","keywords":"melanoma;Tumor microenvironment;CXCR4;Immunotherapy","target":"CXCR4","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6343,"name":6343,"title":"4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches","presenterFirst":"Svetlana","presenterLast":"Hamm","keywords":"Histone deacetylase inhibitor;Combination therapy;Checkpoint","target":"HDAC","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6589,"name":6589,"title":"PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in human colorectal cancer models","presenterFirst":"Stefania","presenterLast":"Napolitano","keywords":"Gastrointestinal cancers: colorectal;MEK Inhibitor;Immunomodulation","target":"MEK","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical in vitro"},{"id":6604,"name":6604,"title":"Targeting PKR-like endoplasmic reticulum kinase modulates metabolism to promote T-cell effector function and PD1 immunotherapy responsiveness","presenterFirst":"Katherine","presenterLast":"Cook","keywords":"T cell;Metabolism;Immunotherapy;Stress response","target":"PERK","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6720,"name":6720,"title":"Targeting HDAC6 to reduce the aggressiveness of metastatic breast cancer in immunotherapy","presenterFirst":"Debarati","presenterLast":"Banik","keywords":"Metastasis;Invasion;Checkpoint;Microenvironment","target":"HDAC6","tumor":"breast_melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6914,"name":6914,"title":"Suppression of myeloid cell arginase activity leads to therapeutic response in Kras mutant lung cancer by activating anti-tumor immunity","presenterFirst":"Juan","presenterLast":"Miret","keywords":"Arginine deprivation;Immune response","target":"arginase1","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":7250,"name":7250,"title":"MPL-5821, a macrophage targeted ESM<sup>TM</sup> p38 MAPK inhibitor, inhibits the production of TLR agonist induced IL-10 whilst sparing T-cell functionality","presenterFirst":"David","presenterLast":"Moffat","keywords":"Macrophages;MAP kinase;Immune response;Interleukin-10","target":"MAPK_TLR","tumor":"ovarian","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7423,"name":7423,"title":"Inhibition of chemokine receptor 2 (CCR2) with a small molecule antagonist enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumors: Reducing tumor size and increasing long term survival","presenterFirst":"James","presenterLast":"Campbell","keywords":"Chemokine receptor;Colorectal cancer;Checkpoint;Gastrointestinal cancers: colorectal","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8050,"name":8050,"title":"The HDAC6 inhibitor Nexturastat A improves<i> in vivo</i> PD-1 immune blockade","presenterFirst":"Alejandro","presenterLast":"Villagra","keywords":"melanoma;Histone deacetylase inhibitor;Immunotherapy","target":"HDC6","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":8151,"name":8151,"title":"The PARP inhibitor rucaparib activates the STING pathway and enhances antitumor responses of immune checkpoint inhibitors in <i>BRCA</i> deficient syngeneic models","presenterFirst":"Andrew","presenterLast":"Simmons","keywords":"PARP;BRCA;Immune response;Checkpoint","target":"PARP1/2","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":8244,"name":8244,"title":"Intratumoral activation of STING with a synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity that effectively combines with checkpoint inhibitors","presenterFirst":"Sarah","presenterLast":"McWhirter","keywords":"Checkpoint;Cancer immunotherapy;Innate immunity;Tumor microenvironment","target":"STING","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8992,"name":8992,"title":"Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study","presenterFirst":"Aung","presenterLast":"Naing","keywords":"Immunotherapy;Pancreatic cancer;Combination therapy;Phase 1","target":"IDO1","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":9276,"name":9276,"title":"A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer","presenterFirst":"Dung","presenterLast":"Le","keywords":"Chemokine receptor;immunosuppression;CCR2/5;tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"colorectal_pancreatic","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10610,"name":10610,"title":"Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma","presenterFirst":"Mohammed","presenterLast":"Milhem","keywords":"CpG oligodeoxynucleotides;CMP-001;TLR9 agonist;PD-1 Resistant","target":"TLR9","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10663,"name":10663,"title":"Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment na\u00efve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)","presenterFirst":"Abraham","presenterLast":"Leung","keywords":"Immunotherapy;Innate immunity;Checkpoint;Head and neck cancers","target":"TLR9","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10731,"name":10731,"title":"Durability of responses to the combination of SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a phase Ib, multicenter study","presenterFirst":"Robert","presenterLast":"Janssen","keywords":"CpG oligodeoxynucleotides;anti-PD-1 therapy;Immunotherapy;SD-101","target":"TLR9","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10861,"name":10861,"title":"Imprime PGG, a soluble yeast \u03b2-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients","presenterFirst":"Mark","presenterLast":"Uhlik","keywords":"Immune response;Imprime PGG;melanoma;Triple negative breast cancer","target":"PAMP","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"clinical"},{"id":10999,"name":10999,"title":"Nanoparticle-incorporated STING activator as an immunotherapeutic for PD-L1 resistant triple-negative breast cancer","presenterFirst":"Ning","presenterLast":"Cheng","keywords":"Macrophages;STING agonist;Nanoparticle;Immunotherapy","target":"STING","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"}]}]}
